An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel

Abstract Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom co...

Full description

Bibliographic Details
Main Authors: Brian Lipworth, Jon Newton, Bhaskar Ram, Iain Small, Jürgen Schwarze
Format: Article
Language:English
Published: Nature Publishing Group 2017-01-01
Series:npj Primary Care Respiratory Medicine
Online Access:https://doi.org/10.1038/s41533-016-0001-y
id doaj-6ff24193c29741bfb36b50aedfe7c9c0
record_format Article
spelling doaj-6ff24193c29741bfb36b50aedfe7c9c02020-12-07T23:54:11ZengNature Publishing Groupnpj Primary Care Respiratory Medicine2055-10102017-01-012711810.1038/s41533-016-0001-yAn algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panelBrian Lipworth0Jon Newton1Bhaskar Ram2Iain Small3Jürgen Schwarze4Ninewells Hospital and Medical School, Scottish Centre for Respiratory ResearchForth Valley Royal Hospital, Forth Valley Health BoardAberdeen Royal Infirmary, Grampian Health BoardPeterhead Surgery, Grampian Health BoardChild Life and Health, The University of EdinburghAbstract Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful allergic rhinitis management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate allergic rhinitis symptoms can be managed successfully in primary care, important gaps in general practitioner training in relation to allergic rhinitis have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista®; Meda), the majority of allergic rhinitis symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of allergic rhinitis in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for allergic rhinitis in primary care that incorporates a considered approach to improve the management of allergic rhinitis symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective allergic rhinitis management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of allergic rhinitis cases. The fundamentals presented in this consensus article should apply in most health-care settings.https://doi.org/10.1038/s41533-016-0001-y
collection DOAJ
language English
format Article
sources DOAJ
author Brian Lipworth
Jon Newton
Bhaskar Ram
Iain Small
Jürgen Schwarze
spellingShingle Brian Lipworth
Jon Newton
Bhaskar Ram
Iain Small
Jürgen Schwarze
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
npj Primary Care Respiratory Medicine
author_facet Brian Lipworth
Jon Newton
Bhaskar Ram
Iain Small
Jürgen Schwarze
author_sort Brian Lipworth
title An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
title_short An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
title_full An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
title_fullStr An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
title_full_unstemmed An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel
title_sort algorithm recommendation for the pharmacological management of allergic rhinitis in the uk: a consensus statement from an expert panel
publisher Nature Publishing Group
series npj Primary Care Respiratory Medicine
issn 2055-1010
publishDate 2017-01-01
description Abstract Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful allergic rhinitis management, and relies mostly on pharmacotherapy. While it is recognised that most mild-moderate allergic rhinitis symptoms can be managed successfully in primary care, important gaps in general practitioner training in relation to allergic rhinitis have been identified. With the availability of new effective combination therapies, such as the novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in a single device (Dymista®; Meda), the majority of allergic rhinitis symptoms can be treated in the primary care setting. The primary objective of this consensus statement is to improve diagnosis and treatment of allergic rhinitis in primary care, and offer guidance on appropriate referral of difficult-to-treat patients into secondary care. The guidance provided herein outlines a sequential treatment pathway for allergic rhinitis in primary care that incorporates a considered approach to improve the management of allergic rhinitis symptoms and improve compliance and patient satisfaction with therapy. Adherence with this care pathway has the potential to limit the cost of providing effective allergic rhinitis management in the UK by avoiding unnecessary treatments and investigations, and avoiding the need for costly referrals to secondary care in the majority of allergic rhinitis cases. The fundamentals presented in this consensus article should apply in most health-care settings.
url https://doi.org/10.1038/s41533-016-0001-y
work_keys_str_mv AT brianlipworth analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT jonnewton analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT bhaskarram analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT iainsmall analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT jurgenschwarze analgorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT brianlipworth algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT jonnewton algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT bhaskarram algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT iainsmall algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
AT jurgenschwarze algorithmrecommendationforthepharmacologicalmanagementofallergicrhinitisintheukaconsensusstatementfromanexpertpanel
_version_ 1724397041136697344